A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH

NCT05128942 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
67
Enrollment
INDUSTRY
Sponsor class

Stopped The SPR001-203 clinical trial did not achieve the primary efficacy endpoint of the absolute change in daily GC dose from baseline at week 24. It was decided to terminate the SPR001-205 in response to the SPR001-203 efficacy data.

Conditions

Interventions

Sponsor

Spruce Biosciences